Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Former Purdue Chairman Sought To Shadow Opioid Sales Reps, Massachusetts AG Suit Says

Executive Summary

Exec was worried Richard Sackler's visits could prompt complaints to FDA's Bad Ad Program; complaint alleges deceptive actions by Purdue execs to boost opioid prescriptions.

You may also be interested in...



Opioid Litigation Avalanche: New York's Expanded Suit Puts More Pressure On Makers And Distributors

Complaint claims Sackler family transferred opioid profits to personal trusts; trials scheduled in federal multidistrict litigation and several state cases.

Purdue's 'Landmark' Settlement With Oklahoma May Be Harbinger Of MDL Resolution

Company is paying nearly $200m for an Oklahoma State University endowment, $12.5m to abate effects of opioid crisis and $60m for litigation costs.

Keeping Track: Two Goal Date Extensions, Another Herceptin Biosimilar Approval, And A BLA Withdrawal

The latest drug development news and highlights from our US FDA Performance Tracker.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

PS124657

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel